LQDA Liquidia Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819576 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,233.6%
TTM net income YoY192.7%
TTM EPS YoY178.2%
Revenue 3-yr CAGR193.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin37.4%
Net margin30.7%
FCF margin33.4%
EBITDA margin37.7%
Returns
ROE131.8%
ROA35.6%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.31x
Interest coverage6.33x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $158.32M | $14.00M | $17.49M | $15.94M | $12.85M |
| Cost of revenue | — | $5.88M | $2.89M | $2.86M | $3.02M |
| Gross profit | — | $8.12M | $14.60M | $13.08M | $9.83M |
| R&D expense | $39.28M | $47.84M | $43.24M | $19.43M | $20.52M |
| SG&A expense | $157.18M | $81.57M | $44.74M | $32.41M | $23.11M |
| Operating income | -$51.38M | -$121.29M | -$73.38M | -$38.77M | -$33.80M |
| Interest expense | $24.17M | $14.65M | $6.27M | $2.34M | $762,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$68.92M | -$128.29M | -$78.50M | -$41.02M | -$34.58M |
| EBITDA | -$49.85M | -$119.10M | -$71.21M | -$35.12M | -$28.18M |
| EPS (basic) | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 |
| EPS (diluted) | -0.80 | -1.63 | -1.21 | -0.67 | -0.70 |
| Weighted avg. shares (diluted) | 86.06M | 78.71M | 64.99M | 60.96M | 49.68M |
| Balance sheet | |||||
| Cash & equivalents | $190.68M | $176.48M | $83.68M | $93.28M | $57.49M |
| Receivables | $54.09M | $2.72M | $4.06M | $5.02M | $2.99M |
| Inventory | $23.80M | $241,000 | $0 | — | — |
| Current assets | $273.40M | $185.10M | $89.90M | $99.81M | $61.28M |
| PP&E, net | $11.84M | $8.30M | $4.48M | $4.15M | $5.02M |
| Goodwill | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M |
| Intangibles | $2.95M | $3.16M | $3.43M | $3.73M | $4.39M |
| Total assets | $327.93M | $230.31M | $118.33M | $129.20M | $93.73M |
| Current liabilities | $135.77M | $41.78M | $18.55M | $8.80M | $7.33M |
| Long-term debt | — | — | — | $19.88M | $10.41M |
| Total debt | — | — | — | $19.88M | $10.41M |
| Total liabilities | $283.19M | $150.94M | $71.04M | $38.78M | $28.46M |
| Shareholders' equity | $44.75M | $79.38M | $47.29M | $90.42M | $65.27M |
| Net debt | — | — | — | -$73.40M | -$47.08M |
| Shares outstanding | 87.20M | 84.68M | 68.63M | 64.52M | 52.29M |
| Cash flow statement | |||||
| Operating cash flow | -$35.69M | -$93.42M | -$41.56M | -$28.59M | -$34.03M |
| Capital expenditure | $4.34M | $4.95M | $1.29M | $592,000 | $107,000 |
| Free cash flow | -$40.02M | -$98.37M | -$42.85M | -$29.18M | -$34.14M |
| Investing cash flow | -$6.34M | -$8.44M | -$11.29M | -$587,000 | -$107,000 |
| Financing cash flow | $59.73M | $194.66M | $43.25M | $64.96M | $26.32M |
| Depreciation & amortization | $1.53M | $2.20M | $2.18M | $3.65M | $5.61M |
| Stock-based compensation | $29.47M | $18.81M | $10.09M | $9.30M | $6.75M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.